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After a day and a half of discussion and debate on the issues of gene discovery, 
of gene ownership and access to genes, the recommendations of the f 40 partici-
pants at the 7th annual National Agricultural Biotechnology Council meeting 
centered on a few critical issues. Those included ensuring the survival of long-
term basic research and inserting social responsibility into the agenda-setting 
process to facilitate discoveries and their development and commercialization 
to ultimately benefit the public.
At each of the previous annual meetings, organizers strove to get participants 
thinking about the issues from all perspectives and to ultimately formulate 
recommendations they can then share with policymakers. This year’s meeting, 
held on the campus of the University of Missouri-Columbia, certainly 
succeeded in achieving its goals. Workshop members and plenary speakers 
from a variety of backgrounds offered suggestions that reflected their concerns 
and goals on the issues of competing rights, the role of governments and public 
institutions, and research policy related to gene discovery, ownership and access.
The timing of the meeting was especially appropriate because agricultural 
biotechnology is advancing at such a rapid rate that obtaining answers to 
questions about gene ownership and access have become critically important. 
The major agenda item was the discussion of policies about intellectual 
property rights (1PR) that control the transfer of knowledge in the molecular 
biology of agricultural commodities to new technology for users. These policies 
generally establish the ownership rights to intellectual property, the obligation 
to disclose inventions and conditions of access, the rights of research sponsors 
to intellectual property resulting from funded research, and the rights from 
informal innovation by farmers.
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As one can imagine, the viewpoints set forth were as varied as the 12 
speakers and the conference participants who represented consumer groups, 
industry, government and academia. For example, Wisconsin family farmer, 
John Kinsman, who is also President of the National Family Farm Defenders 
and the Wisconsin Family Farm Defense Fund, focused on the rights of farmers 
who feel a strong need for self determination, while Ronald Sederoff, Professor 
of Forestry and Director of the Forest Biotechnology Group at North Carolina 
State University, voiced his concern about gene ownership restricting access for 
research. Representing one view of industry, Jack Tribble, Patent Council for 
Merck & Co., Inc., explained there is a need for cooperation among industry 
and university researchers so that each can achieve its goals and objectives.
Speaking about defining and ascribing ownership to genes and farmers’ 
rights, Jose Solleiro, Senior Researcher in the Centre for Technological 
Innovation of the National University of Mexico, asked “how do you put a 
value on generations of background knowledge that is being tapped for 
agricultural biotechnology?” In his opinion, more consideration needs to be 
given to the informal innovation of indigenous peoples, both nationally and 
internationally.
The speakers echoed essentially the same concerns, namely the effects IPRs 
have on public and private research efforts and ultimately the production and 
delivery of products which are essential if society is to benefit from the public 
and private investment.
. . the heart of the research enterprise is being constrained by the 
protection of intellectual property owned by others,” Sederoff said. It is his 
opinion that “Constraints on the research enterprise have significant implica-
tions for the well-being of society. When researchers are restricted in attempts 
to extend our knowledge of the world around us, society pays a cost of lost 
innovation, which is crucial for economic development and the well-being of 
our citizens.”
Concurring was Kathleen Merrigan, senior analyst with the Henry A. Wallace 
Institute for Alternative Agriculture, who stressed that: patents influence the 
university research agenda, overly broad patents stifle research, and patents lead 
to increased research costs. She explained that the current IPR system does not 
meet today’s needs and suggested that a radically different system is needed.
Yet Leanna Lamola, Attorney, sees IPR as helping to maintain the identity and 
profitability of value-added proprietary factors of identity-preserved varieties. 
Production contracts are the main mechanism by which producers will 
participate in identity-preserved systems, she said, adding that risk manage-
ment is the primary advantage of contract production for both the producer and 
the contractor. By controlling the timing, quantity, quality and specifications of 
production, economic efficiencies can be realized. However, production 
contracts can also present new risks, such as an inability to learn the true 
market value of products. Producers may increase returns in identity-preserved
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systems by moving into downstream activities such as processing. Likewise, 
producers may decide to fund the development of identity-preserved varieties 
through research agreements or other strategic alliances with private or public 
organizations.
In addition, participants identified several critical areas of 1PR that need 
further consideration: partnerships, valuation, proportionality and compensa-
tion. Kinsman and Solleiro both talked about proportionality: How do you put 
a proportional value on knowledge? Participants also agreed that IPR should be 
examined in relation to the public good, and policies may need to be estab-
lished regarding access to proprietary information in agricultural technology. 
Also, public access is needed to provide researchers with genes and tools to 
facilitate their use; a need exists to reassess the research exemption; and 
freedom of inquiry is required to preserve the research capability. Merrigan 
challenged the participants to come up with some action items, not just a set 
of passive recommendations.
Indeed, the recommendations from the workshops were action-oriented and 
specific, centering on concerns about the future of basic research and social 
responsibility in the agenda-setting process. It was felt by participants that 
policies should balance the social good versus private gain; ownership of genes 
can have a negative impact on research and skew the research agenda; and 
patents should have the appropriate breadth. In the U.S., the standards of 
patentability (novelty, utility and non-obviousness) should be strictly applied in 
agricultural biotechnology. In addition, IPR should be examined in relation to 
the public good and equity should be negotiated. With reference to the access 
to proprietary information in agricultural technology, new principles may need 
to be established. A need exists to reassess the research exemption. Freedom of 
inquiry is required to preserve the research capability. One important immediate 
concern is to deal with policy issues at the interface between ownership and 
access. The future of agricultural biotechnology requires aggressive discovery 
and equitable access. Then how is the balance achieved at the conjunction of 
ownership and access? When is access to be benefited at the cost of ownership 
and vice versa?
Specific recommendations developed in the workshops can be found on 
pages 13 to 17. The full workshop reports begin on page 29.
In line with the charge given by Merrigan at the first evening session, the 
following action items have been gleaned from the synthesis of the meeting 
activities:
1. Clarify the research exemption for use by public research institutions.
For example, clarify this exemption to enable gene sequence information 
and proven information from all areas to be available for research. The 
need is to preserve freedom of inquiry and investigation and curiosity- 
driven research in public institutions, even knowing that these 
institutions also engage in technology transfer.
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2. Establish policy in agricultural biotechnology that fosters legitimate 
germplasm exchange mechanisms to ensure the fairness of future 
transactions for the public good.
3. Foster cooperation among stakeholders in agricultural biotechnology. 
Partnerships are important, but they should be set up in such a way as to 
not violate the mission and direction of research at public institutions. 
New partnerships should be forged, but not at the expense of long-term 
research. The concept of mutual responsibilities among universities, 
industry and government to maintain vision and mission provides a 
useful framework for action.
4. Address the conflict between social good and private gain with reference 
to gene ownership. The main concern is the possible negative impact of 
ownership on universities or, more broadly, on the research enterprise.
5. Be open to other 1PR systems that might be more appropriate for other 
countries, and decide what kinds of agreements and partnerships are 
needed with the U.S. IPR system.
6. Consider what is the appropriate breadth of patent claims. This will 
mean looking at public-private interfaces and the various roles of 
different institutions.
7. Endeavor to create conditions to facilitate access to genetic resources 
through mutually agreed upon terms, informed consent, and sharing of 
benefits in a way that is clear up front. This would include working to 
empower third world farmers and indigenous peoples and countries to 
recapture some equitable compensation for their genetic material.
Clearly, each interest group must be actively involved in the development and 
promotion of new agricultural products. This is especially important for the 
general public who may not have the background and details to make informed 
decisions. As Richard Flavell of the John Innes Centre, Norwich, UK, advised, 
“The consumer acceptance of transgenic crops is not straightforward, and a 
major public educational effort is needed.” And according to Merrigan, there 
are several ways to help the public become more involved with the research 
going on at universities, in government agencies, and even within industry.
It was that agreement and understanding that prevailed . . . cooperation 
among all interest groups, and the recognition and understanding that not 
everyone will come to the decision-making table with the same background or 
perspective.
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Plenary  Session  highlights
NABC 7 was organized around three plenary sessions: Gene Mapping and the 
Political Economy of Agricultural Research; Ownership: Economic, Legal and 
Institutional Issues; and Access: Public and Private. Speakers at these sessions 
provided a common core of information for workshop debates and hallway 
dialogue.
Gene  Mapping  and  the  Political  Economy  of  Agricultural  
Research
In the first plenary session the two keynote speakers dealt with the status of 
gene mapping and its implications for gene discovery.
Richard B. Flavell, John Innes Centre
Flavell discussed genes and gene mapping for agriculture. He pointed out that 
new combinations of genes in plants are one of the most valuable resources 
for future civilizations because they are sources of better food, feed and fiber; 
economic growth; potential stability; human health and a sustainable environ-
ment. Molecular biology is removing the constraints of classical breeding by 
detecting the presence of genes by their chemistry, and uncovering genetic 
variation. With the use of computers to determine the sequence and function 
of genes, the pace of gene mapping on chromosomes has increased rapidly. For 
example, 10,000 to 15,000 of the 25,000 genes of rice have been identified. In 
10 years all the rice genes should be identified along with their chromosomal 
location. Genetic information from bacteria to humans is being pooled and the 
field of molecular biology is being unified. Information of great value for animal 
gene sequence and function will come from the human genome project.
The consequences of this international effort in agricultural biotechnology 
are many: genetic determination of key traits will become known at the molecu-
lar level; geneticists working on related crops will use each other's information 
much more than they do now; plant breeding will be increasingly automated 
and selections will be performed by computer without growing plants; new 
genetic variation in defined genes will be produced at will; and increasingly 
crops will be modified to serve new customers, markets and industries. Plant 
improvement programs will be accelerated. There will be increased patenting 
of genes, and transgenic crops will require the adherence to specific legislation 
that needs to be harmonized globally. A major concern is that the patenting of 
genes will inhibit the free global flow of germplasm for use in other breeding 
programs. The consumer acceptance of transgenic crops is not straightforward, 
and a major public educational effort is needed. Flavell’s paper begins on 
page 51.
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Kathleen A. Merrigan, Henry A. Wallace Institute for Alternative Agriculture
Merrigan spoke persuasively about unresolved problem areas of gene discovery 
and agricultural biotechnology. She pointed out that the public is now not 
engaged with the issues of agricultural biotechnology, yet their buy-in is 
critical. Current 1PR policies of broad patents have a negative impact on 
research in agricultural biotechnology, including conflict of interest issues 
and increased transactional costs. Regulatory gaps do persist. For example, 
currently only voluntary action is needed to prevent and/or delay the onset 
of public opposition to plants genetically engineered to contain pest or disease 
resistance factors. She offered several ways for the public to become more 
involved in biotechnology policy, including having lay people involved 
in decision-making at universities, seeking the opinions of leaders in the 
community, and having all undergraduates take a citizenship course that 
covers biotechnology. Merrigan’s paper can be found beginning on page 61.
Gene  Ownership : Economic , Legal  and  Institutional  Issues
The second plenary session presented four different viewpoints on the 
economic, legal and institutional issues surrounding gene ownership.
Ronald Sederoff, North Carolina State University
Sederoff spoke about gene mapping of forest trees, specifically the loblolly pine. 
He was particularly concerned about gene ownership restricting access for 
research. A key enzyme for molecular biology in forest biotechnology (Taq 
polymerase) has been patented by The Perkin-Elmer Corporation. This has 
essentially made the enzyme unavailable to researchers because of its high cost, 
and provides an example of how public research is restricted through patenting. 
At the same time, there is increased pressure on university scientists to work on 
short-term projects at the sacrifice of longer term fundamental research, thereby 
eroding our intellectual capital. Research being done at public institutions is 
affected by the patent process and the funding by private companies.
To foster long-term basic research in biotechnology, Sederoff advocated a 
research exemption from patents for public research. Many scientists have the 
false perception that there is a general exemption for university or government- 
based research if it is purely philosophical in purpose. Yet it has been argued 
that universities have lost the claim to a philosophical exemption because they 
file patents, exercise patent rights, and receive fees for licensing and royalties. 
Sederoff’s paper can be found beginning on page 71.
Jack L. Tribble, Merck & Co., Inc.
Gene ownership versus access: meeting the needs was discussed by Tribble 
who pointed out that patents are vital for industrial research incentives. He 
indicated that recent advances in the pharmaceutical industry made possible
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by biotechnology were achieved because of the patent incentive. At the same 
time, he said he understands the need for public research, and sees an inter-
dependence among industry and university researchers. Tribble discussed how 
policy attempts, such as the Bayh-Dole Act, to solve the problems of research 
access have been positive in intent, but largely unsuccessful. This legislation 
intended to make information and germplasm openly available for research 
purposes, but instead there has been a federal policy shift towards patents and 
away from putting information into the public domain.
He explained that Merck’s policy is to make materials available for research 
tools distinct from licensing for products. Merck supports a policy of licensing 
of patented inventions for research use, separately from licensing for commer-
cial development of products for sale. For example, the company has developed 
the Merck Gene Index Project, a catalog of sequence data, which will make 
cDNA sources available to all scientists. He indicated that Merck wants to foster 
collaboration among commercial laboratories and academic and governmental 
laboratories to allow science to advance, foster competition among commercial 
labs, and speed discovery of new products to benefit the public. See page 97 for 
Tribble’s paper.
Leanna M. Lamola, Attorney
Lamola spoke about intellectual property rights in agricultural genetics and 
their function in industrial agriculture. She indicated that identity-preservation 
is one type of an end-use oriented marketing system that is changing the 
structure of modern production agriculture. Intellectual property rights play 
a central role in identity-preserved systems, such as Calgene’s Flavr Savr™ 
tomato, because they allow rights holders to reduce investment risk, obtain 
premium prices, preserve the identity, and control the use of value-added 
factors in downstream or upstream arenas. According to Lamola, production 
contracts are the main mechanism by which producers will participate in 
identity-preserved systems. The producers may decide to fund the development 
of identity-preserved varieties through research agreements or other strategic 
alliances with private or public organizations. Such activities will add to the 
need to re-examine the traditional relationship between the land-grant 
university and agriculture.
Lamola suggested that there are a number of factors that can impact a 
contract producer’s ability to obtain higher returns, including relative bargain-
ing power. Recently, some contract producers have organized into associations 
to improve their bargaining position. Perhaps the most well known is the 
National Contract Poultry Growers Association, which has lobbied for state 
and federal legislation designed to prohibit unfair practices by integrators. 
Lamola’s entire paper can be found beginning on page 87.
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Jose Luis Solleiro, National University of Mexico
Solleiro, who spoke in this plenary session and the third one, talked about 
defining and ascribing ownership to genes and farmers’ rights. An issue close 
to the heart of ownership is valuation, he said. For example, how do you sort 
out the proportion of value added by an inserted gene from a plant found in a 
developing country when engineered into a plant variety originally developed 
in a long-term breeding program at a public institution supported by public 
U.S. funds? Today in agricultural biotechnology we are moving more toward an 
approach of putting different pieces of knowledge together, which is necessary 
to move forward. But how do we sort out ownership, credit and compensation?
According to Solleiro, it is essential to improve the legal framework to deal 
with these issues at all levels and to build domestic capacities to identify, 
conserve and use genetic resources, and better negotiate the terms of future 
agreements. See page 109 for his paper.
Access  to  Genes : Public  and  Private
The third plenary session presented four different viewpoints on the issue of 
public and private access to genes of importance to agricultural biotechnology.
Henry L. Shands, United States Department of Agriculture
Shands spoke about access: bartering and brokering genetic resources. He 
indicated that ownership of genetic resources has become a vocal issue 
surrounding the Convention on Biological Diversity, ostensibly because of 
the pharmaceutical industry’s profits from drugs developed from medicinal 
plant sources. However, much of the movement to curb the exodus of plant 
genetic resources from developing countries came as a result of developed 
countries intellectual property laws giving companies a legal basis to protect 
their varieties and inbred strains for hybrid production. He said that the most 
severe problem associated with the international access to genetic resources 
is that discussions are held in a political rather than a scientific context, 
without a logical concern for such issues as food quality and safety. The 
world’s agriculture is inextricably connected, and it is not sufficient to think 
about our own country’s system. United States Department of Agriculture has 
a policy of free exchange under the National Plant Germplasm System. How-
ever, with increasing restrictions to access of genetic information, the sharing 
of information by scientists will become a more serious problem in the future. 
He argued that the international community should provide open access to all 
genetic resources for food and agriculture, engage Material Transfer Agree-
ments (MTAs) to enable research and breeding with the material, facilitate a 
brokerage system for this exchange, establish a tracking system and compensa-
tion mechanism for germplasm, and promote a bartering system in which 
access is provided in exchange for training and/or technology. In addition, he 
said that an international fund is needed to support biodiversity. See page 117 
for his paper.
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Peter R. Day, Rutgers, the State University of New Jersey 
While discussing the impact of patents on plant breeding using biotechnology, 
Day admitted that the introduction of plant variety rights encouraged the 
development of private sector plant breeding. Although this has led to a decline 
in academic breeding programs, there remain many opportunities for germ- 
plasm enhancement research in our universities. Biotechnology patents are 
bringing about similarly profound, but far more complicated changes. Enhance-
ment through transformation almost always involves the use of patented genes 
and/or methods. Although investigators are free to use patented properties for 
research, there are severe constraints in the developed as well as the developing 
world to using them in agriculture to benefit farmers. Many believe that the 
constraints are justified as the price for protecting intellectual property. He 
noted that academic scientists are becoming just as involved as their colleagues 
in industry.
The extent of patenting single genes or enzymes that are part of a larger 
system of research has made basic research extremely complex. For example, 
Rutgers' scientists developing new cultivars for field tests have to take existing 
patents into account and have each interested party agree to use under a license 
that specifies payment required. Several of these licensing agreements may 
be necessary for one experiment to be conducted. The scope and extent of 
patenting is growing within industry and within U.S. universities and other 
public research arenas. For example, at Stanford University there is one patents 
officer for each ten faculty members. He agreed with Sederoff that universities 
are involved in research for profit, and he cautioned that scientific research with 
a specific product in mind can be a shortsighted approach. A related access 
issue arises in business decision-making with reference to minor crops. If a 
company is focusing only on top-priority opportunities, it may close down 
access to genes important for minor crops or for what seems to a company to 
be a marginal opportunity, but which might meet some important public need. 
The question can be posed as: How can we ensure that the public benefits in a 
wide array of ways through access to discoveries? His paper begins on page 79.
John G. Kinsman, National Family Farm Defenders and the Wisconsin 
Family Farm Defense Fund
During his presentation, Kinsman spoke about farmers’ rights: what is fair? He 
focused on the rights of farmers who feel a strong need for self-determination 
and now despair about their situation. He asked the question how can channels 
of communication between farmers and biotechnologists be opened up? He 
answered by saying that long term talks and constructive cooperation are 
needed and condescending attitudes towards farmers and hasty decisions 
should be avoided. He also said that IPR should be considered a lease rather 
than a right. What are the financial implications? What are the impacts of IPR? 
He feels that farmers were misled by those who assured them that agricultural
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chemicals are safe, in light of the reported contamination of well-water in 
the U.S. by these products. He commented how can we as grassroots farmers 
and consumers be assured of proper control and safeguards to our livelihood 
in agricultural biotechnology? He pointed out that the ethical and moral 
implications of emerging technologies need to be thoroughly examined and 
weighed for their impact on cultures and economies. Will the economic and 
lifestyle impact be progressive and stable, or will the impact be devastating 
to certain regions, countries or cultures? He wanted to know, as an average 
American citizen, how his basic rights will be affected. What safeguards are 
in place or need yet to be developed to protect the health of people and the 
environment in the release of genetically engineered bacteria and other life 
forms? See page 105 for Kinsman’s paper.
Jose Luis Solleiro, National University of Mexico
Speaking again during this session, Solleiro discussed IPR: key to access or 
entry barrier for developing countries. He indicated that IPR has become a 
basic objective of companies seeking to commercialize biotechnology derived 
products. This renewed interest in IPR has already triggered unilateral actions, 
such as those undertaken under the U. S. Trade and Tariffs Act as well as mul-
tilateral negotiations within the World Intellectual Property Organization and 
the General Agreement on Tariffs and Trade (GATT). Intellectual Property 
Rights played an important role in the North American Free Trade Agreement 
(NAFTA) negotiations. Many developing countries have already adopted 
modern IPR legislation, granting protection for most biotechnology develop-
ments. Solleiro described the Rio Convention on Biodiversity which granted 
access to genetic resources to individual governments, depending on their 
own domestic policy. He made the important distinction, though, that “free 
access does not mean free of charge.” Conventions, powerful countries and 
big companies claim that developing countries have protective rights, but he 
explained they cannot enforce them. He gave a hypothetical example illustrat-
ing how a small company in Mexico would not have the resources to sue a 
large multi-national company for infringement. He indicated that the system 
is still incomplete, and in its present state the IPR system benefits large 
multi-national corporations who receive patents and lawyers who sift through 
the mass of legal intricacies created by the system. From the perspective of 
developing countries, concern for protection under an IPR system takes a 
back seat to domestic concerns over such issues as a weak domestic industry, 
research limitations, conservative attitudes, poor economy and the lack 
of concern over agricultural education. He concluded that, for a country 
like Mexico, a protective system of IPR is not sufficient to allow access to 
biotechnology innovations. There should be a national commitment to 
agriculture research and development, and an adequate legal framework to 
handle international technology transfer. Solliero’s paper begins on page 123.
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